[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334240-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334240-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","quantication-of-pd-l1-expression-and-tumor-mutational-burden-in-biologically-distinct-advanced-pancreatic-cancers-responding-to-pembrolizumab-case-reports","Quantiﬁcation of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab - case reports","","Checkpoint therapy represents a major advance in oncology, yet it has been largely ineffective in pancreatic cancer. This report describes two advanced pancreatic cancer cases, one with conventional-treatment failure and another with recurrence after prior therapy, in which tumor tissue sequencing was used to quantify PD-L1 expression and tumor mutational burden. After assessing predictive biomarkers such as combined positive score and TMB, both patients received checkpoint blockade and achieved durable radiographic responses. The work supports evaluating CPS and TMB in refractory or recurrent settings when considering ICB initiation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/quantication-of-pd-l1-expression-and-tumor-mutational-burden-in-biologically-distinct-advanced-pancreatic-cancers-responding-to-pembrolizumab-case-reports/334240/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/quantication-of-pd-l1-expression-and-tumor-mutational-burden-in-biologically-distinct-advanced-pancreatic-cancers-responding-to-pembrolizumab-case-reports/334240.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does this case report address in pancreatic cancer treatment?","Question",{"text":63,"@type":64},"The report addresses the limited effectiveness of immune checkpoint blockade in pancreatic cancers, particularly pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were predictive biomarkers assessed before starting checkpoint blockade?",{"text":68,"@type":64},"Tumor tissue was sequenced and analyzed for PD-L1 expression, using measures such as combined positive score (CPS) and tumor mutational burden (TMB), including high TMB.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the outcomes after immunotherapy in the two cases?",{"text":72,"@type":64},"In both cases, checkpoint blockade led to durable radiographic responses with sustained clinical benefit reflected by imaging and symptom control.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334240,1790131970,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Case Report  \nPUBLISHED 02 December 2024 DOI 10.3389/fimmu.2024.1452543  \nOPEN ACCESS  \nEDITED BY  \nNicholas Adam Young,  \nPrivate Health Management Inc, United States  \nREVIEWED BY  \nPhilippe Rochigneux,  \nInstitut Paoli-Calmettes (IPC), France Ajit Kumar Sharma,  \nNational Institutes of Health (NIH), United States  \nSid P. Kerkar,  \nKerkar Consulting LLC, United States  \n*CORRESPONDENCE  \nPaul Fanta  \n [pfanta@health.ucsd.edu](pfanta@health.ucsd.edu)  \nRECEIVED 21 June 2024  \nACCEPTED 14 November 2024  \nPUBLISHED 02 December 2024  \nCITATION  \nLi KY, Lowy AM and Fanta P (2024)  \nQuantiﬁcation of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding topembrolizumab: case reports.  \nFront. Immunol. 15:1452543 .  \ndoi: 10.3389/fimmu.2024.1452543  \nCOPYRIGHT  \n© 2024 Li, Lowy and Fanta. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nQuantiﬁcation of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab:  \ncase reports  \nKevin Y. Li 1,2, Andrew M. Lowy 1,2 and Paul Fanta 2,3*  \n1 Department of Surgery, Division of Surgical Oncology, University of California, San Diego, San Diego, CA, United States, 2 Moores Cancer Center, University of California, San Diego, San Diego, CA, United States, 3 Division of Hematology Oncology, Department of Medicine, University of California, San Diego, San Diego, CA, United States  \nBackground: The advent of checkpoint therapy is one of the most important recent advancements in cancer therapy. Though checkpoint therapy is a mainstay in some cancers, it has been largely ineffective in treating cancers of the pancreas. Pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors are seldom responsive to checkpoint inhibition.  \nCase presentations: Here we present two cases of advanced pancreatic cancers that either failed to respond or recurred following conventional treatments. Tissue from each tumor was sequenced and analyzed for PD-L1 expression. Each patient was started on checkpoint blockade after assessing for a predictive biomarker, either the combined positive score or the tumor mutational burden. In each case, checkpoint blockade led to durable radiographic responses.  \nConclusions: We therefore propose that it is reasonable to assess combined positive score and tumor mutational burden in refractory or recurrent pancreatic cancers when initiation of ICB is being considered.  \nKEYWORDS  \npancreatic adenocarcinoma, immunotherapy, CPS, TMB, pancreatic neuroendocrine tumor  \nIntroduction  \nPancreatic malignancies, such as pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumors (PNETs) are generally incurable when systemic disease is present, and with rare exceptions they have proven refractory to immune checkpoint blockade (ICB) . The reasons for this are multiple, including a relative lack of  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \ncytotoxic T-cell (CTL) inﬁltration (1) . Although various biomarkers for predicting ICB response are undergoing pre-clinical and clinical investigation, there is clearly no deﬁnitive test. Therefore, we are currently left to identify predictors of ICB efﬁcacy based on existing biomarkers used in more responsive malignancies.  \nThe Combined Positive Score (CPS) and Tumor Proportion Score (TPS) are tissue based, immunohistochemical scores that provide quantiﬁcation of PD-L1 expression. Both metrics have been proposed as predictors of responsiveness to ICB in nonpancreatic malignancies. Simil","cbCaiiiSEtbvZxq2","https://ap.wps.com/l/cbCaiiiSEtbvZxq2","pdf",5776302,"English","# Introduction\n## Checkpoint inhibition challenges in pancreatic cancer\n## Biomarkers for PD-L1 quantification and ICB response\n# Methods\n## Informed consent and case reporting approach\n# Case presentation\n## Case presentation #1\n## Case presentation #2","[{\"question\":\"What problem does this case report address in pancreatic cancer treatment?\",\"answer\":\"The report addresses the limited effectiveness of immune checkpoint blockade in pancreatic cancers, particularly pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors.\"},{\"question\":\"How were predictive biomarkers assessed before starting checkpoint blockade?\",\"answer\":\"Tumor tissue was sequenced and analyzed for PD-L1 expression, using measures such as combined positive score (CPS) and tumor mutational burden (TMB), including high TMB.\"},{\"question\":\"What were the outcomes after immunotherapy in the two cases?\",\"answer\":\"In both cases, checkpoint blockade led to durable radiographic responses with sustained clinical benefit reflected by imaging and symptom control.\"}]","Quantiﬁcation of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab - case reports | PDF",1790005911,15]